Episode 60: Hims & Hers
Send us Fan Mail
In this episode of Petri Dish Perspectives, we dive into the rise of Hims & Hers Health, the telehealth company that transformed direct-to-consumer healthcare and challenged traditional medicine. Founded in 2017 by Andrew Dudum, Hims & Hers built a billion-dollar business by removiâŠ
đš EXCLUSIVE: Hims board member David Wells on why he bought $1.2M of Hims
Thanks to our partner:Superpower - https://superpower.com
In episode 72 of Hims House, Jonathan Stern interviews David Wells, Hims board member and former Netflix CFO, about his recent $1.2 million open-market purchase of Hims shares. Wells explains why he believes the company is at an inflection âŠ
Healthcare is BrokenâThis Company Wants to Fix It
Ed Elson sits down with Andrew Dudum, co-founder and CEO of Hims & Hers, to discuss why the company went public so early, how it made GLP-1s more affordable, and whether healthcare regulation has gone too far. They also explore why Hims & Hers chose to disrupt the system instead of working within iâŠ
Hims & Hers Q2 2026: Growth Up, Margins Down
Send us Fan Mail
Hims & Hers accelerated revenue growth while gross margin fell twelve percentage points. Management calls the quarter proof that the model can scale. The income statement asks for patience.In this episode of Quarters, Andrew Dudum argues that Hims can expand access to care and remaâŠ
Hims Preps Peptides, Abbott Syncs with Google, Amazon Targets Pharma
August 12, 2026: Your daily rundown of health and wellness news, in under 5 minutes.
Today's top stories:
Hims CEO Andrew Dudum says the company plans to offer approved peptides by year-end, leveraging 19% subscriber growth to 2.9 million as a distribution channel
Abbott's Lingo glucose data iâŠ
Hims Preps Peptides, Abbott Syncs with Google, Amazon Targets Pharma
August 12, 2026: Your daily rundown of health and wellness news, in under 5 minutes.
Today's top stories:
Hims CEO Andrew Dudum says the company plans to offer approved peptides by year-end, leveraging 19% subscriber growth to 2.9 million as a distribution channel
Abbott's Lingo glucose data iâŠ
AI âGeniesâ & Hims & Hers CEO Andrew Dudum 8/18/26
In an exclusive, rare interview, CEO and co-founder of Hims & Hers Andrew Dudum sits down with Andrew Ross Sorkin. Dudum maps out his vision for an AI-enabled American healthcare system, comments on the FTCâs lawsuit, and reflects on his companyâs impact on GLP1 access and affordability. CNBCâs AleâŠ
$50 Zepbound Incoming? China Has US in a GLP-1 âChokeholdâ
Could GLP-1 medications eventually cost just $40 to $50 per month? Hims & Hers CEO Andrew Dudum thinks so, and if heâs right, it could completely change access to obesity treatment in America.
But getting there may depend on something most patients have never heard of: the global peptide manufactuâŠ
The Grand Roundup: Q2 earnings special â AI ROI finally shows up, managed care's comeback, Molina's ACA spiral, Hims' Bluetooth pill box pitch, and more
Kevin and Martin are out this week, so TGR is running our Q2 earnings wrap-up with HTN's Sean Leimbach, covering the quarter across the HTN Research coverage universe.
First up: AI. Centene's Sarah London gave what Kevin calls âthe quote of earnings seasonâ on the risk of spending big with no returâŠ
OpenLoop CEO: the peptide gray market is 2-3x bigger than analyst estimates, likely $6-8 billion
Thanks to our partner:Superpower - https://superpower.com
In episode 80 of Hims House, Jonathan Stern talks with Dr. Jon Lensing, co-founder and CEO of OpenLoop, the white-label company that runs telehealth behind the scenes for other brands. Lensing started OpenLoop out of the University of Iowa'sâŠ
PODCAST SĂKMOTOR
Du kan anvÀnda vÄr webbplats för att söka efter3,822,234podcaster och195,479,508avsnitt efter personer, platser eller Àmnen.
En investering i kunskap ger bÀst avkastning, sÄ jag lyssnar pÄ poddar.
‐ Benjamin "Llamacorn" Franklin
REDIGERA
Tack för att du hjÀlper till att hÄlla databasen över podcaster uppdaterad.
